Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial

Journal of the American Academy of Dermatology

Volumn 70, Issue 3, 2014, Pages 583-584

  Okon, Lauren ^a,b   Rosenbach, Misha ^a,b   Krathen, Michael ^a,b   Rose, Mathew ^a,b   Propert, Kathleen ^c   Okawa, Joyce ^a,b   Werth, Victoria ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Perelman Center for Advanced Medicine   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE;

ARTHRALGIA; CUTANEOUS LUPUS AREA AND SEVERITY INDEX; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; HUMAN; LETTER; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; SKIN LUPUS ERYTHEMATOSUS; TREATMENT DURATION; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; BIOPSY, NEEDLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; PATIENT SAFETY; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84894117144     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.11.007     Document Type: Article

References (5)

1. T.S. Housman, J.L. Jorizzo, M.A. McCarty, S.E. Grummer, A.B. Fleischer, and P.G. Sutej Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus Arch Dermatol 139 2003 50 54 (Pubitemid 36091574)
2. S. Moghadam-Kia, S. Chilek, E. Gaines, M. Costner, M.E. Rose, and J. Okawa et al. Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients Arch Dermatol 145 2009 255 260
3. J. Cortes-Hernandez, G. Avila, M. Vilardell-Tarres, and J. Ordi-Ros Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus Arthritis Res Ther 14 2012 R265
4. S. Bastuji-Garin, S. Ochinsky, P. Bouche, R.K. Gherardi, C. Duguet, and Z. Djerradine et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients J Invest Dermatol 119 2002 1020 1026 (Pubitemid 35430479)
5. I. Braunstein, N.G. Goodman, M. Rosenbach, J. Okawa, A. Shah, and M. Krathen et al. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare J Am Acad Dermatol 66 2012 571 582